Apogee Therapeutics will announce Phase 2 APEX trial data for zumilokibart on March 23, 2026, followed by a conference call.
Quiver AI Summary
Apogee Therapeutics, Inc. announced that it will release 52-week data from the Phase 2 APEX trial of its drug zumilokibart on March 23, 2026. Following the announcement, a conference call and webcast will be held at 8:00 a.m. ET to discuss the findings. Apogee is a clinical-stage biotechnology company focused on developing novel biologics aimed at treating inflammatory and immunology conditions, including atopic dermatitis, asthma, and eosinophilic esophagitis. With its advanced antibody programs, Apogee aims to achieve differentiated efficacy and dosing to meet the needs of patients underserved by current therapies. Interested individuals can access the webcast through the company's website, and a replay will be made available afterward.
Potential Positives
- Apogee Therapeutics is set to announce the 52-week data from the Phase 2 APEX trial of its lead program, zumilokibart, indicating progress in clinical development.
- The company will provide a live conference call and webcast to discuss the trial results, promoting transparency and engagement with investors.
- Zumilokibart targets significant unmet needs in large markets such as atopic dermatitis (AD) and asthma, positioning Apogee favorably in the competitive biotechnology sector.
- Apogee's strategy of utilizing advanced antibody engineering and focusing on validated targets suggests potential for differentiated and effective therapies in inflammatory and immunology markets.
Potential Negatives
- Announcement of upcoming data from the Phase 2 APEX trial indicates that the company is still in early clinical stages, which may raise concerns about the length of time required to bring products to market.
- The focus on a single candidate, zumilokibart, in the press release could create perceived over-reliance on this program, heightening risks if the results are unfavorable.
- As the company is described as clinical-stage, it may face skepticism regarding its ability to transition from trials to commercialization effectively.
FAQ
When will Apogee Therapeutics report Phase 2 APEX trial results?
Apogee Therapeutics will report the Phase 2 APEX trial results on March 23, 2026.
How can I access the webcast of the APEX trial results?
The webcast can be accessed via the link provided on Apogee's Investors section of their website.
What is the focus of Apogee Therapeutics' research?
Apogee Therapeutics focuses on developing novel biologics for inflammatory and immunology markets, including treatments for AD, asthma, and EoE.
What is the significance of zumilokibart?
Zumilokibart is Apogee's most advanced program targeting atopic dermatitis and other I&I conditions, aiming for best-in-class efficacy.
Who can I contact for more information about Apogee Therapeutics?
You can contact Noel Kurdi, VP of Investor Relations, at [email protected] for more information.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$APGE Insider Trading Activity
$APGE insiders have traded $APGE stock on the open market 54 times in the past 6 months. Of those trades, 0 have been purchases and 54 have been sales.
Here’s a breakdown of recent trading of $APGE stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT sold 1,750,000 shares for an estimated $133,525,000
- MICHAEL THOMAS HENDERSON (Chief Executive Officer) has made 0 purchases and 20 sales selling 140,000 shares for an estimated $10,153,009.
- CARL DAMBKOWSKI (Chief Medical Officer) has made 0 purchases and 18 sales selling 56,495 shares for an estimated $3,823,078.
- JANE HENDERSON (Chief Financial Officer) has made 0 purchases and 15 sales selling 19,500 shares for an estimated $1,408,706.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$APGE Hedge Fund Activity
We have seen 130 institutional investors add shares of $APGE stock to their portfolio, and 92 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 1,576,626 shares (+324.4%) to their portfolio in Q4 2025, for an estimated $119,003,730
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,554,546 shares (+107879.7%) to their portfolio in Q4 2025, for an estimated $117,337,132
- FMR LLC added 1,308,576 shares (+18.9%) to their portfolio in Q4 2025, for an estimated $98,771,316
- POINT72 ASSET MANAGEMENT, L.P. removed 1,230,377 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $48,882,878
- BLACKROCK, INC. added 1,097,968 shares (+40.9%) to their portfolio in Q4 2025, for an estimated $82,874,624
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,055,464 shares (-81.8%) from their portfolio in Q3 2025, for an estimated $41,933,584
- PERCEPTIVE ADVISORS LLC added 978,662 shares (+72.4%) to their portfolio in Q4 2025, for an estimated $73,869,407
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$APGE Analyst Ratings
Wall Street analysts have issued reports on $APGE in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 01/06/2026
- Stephens & Co. issued a "Overweight" rating on 12/17/2025
- Deutsche Bank issued a "Buy" rating on 12/10/2025
- Craig-Hallum issued a "Buy" rating on 11/03/2025
- Mizuho issued a "Outperform" rating on 10/21/2025
- RBC Capital issued a "Outperform" rating on 09/25/2025
To track analyst ratings and price targets for $APGE, check out Quiver Quantitative's $APGE forecast page.
$APGE Price Targets
Multiple analysts have issued price targets for $APGE recently. We have seen 8 analysts offer price targets for $APGE in the last 6 months, with a median target of $99.0.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $83.0 on 03/18/2026
- Julian Harrison from BTIG set a target price of $137.0 on 03/16/2026
- David Nierengarten from Wedbush set a target price of $95.0 on 03/03/2026
- Brian Abrahams from RBC Capital set a target price of $82.0 on 03/03/2026
- Sudan Loganathan from Stephens & Co. set a target price of $95.0 on 12/17/2025
- David Hoang from Deutsche Bank set a target price of $103.0 on 12/10/2025
- Adam Vogel from Craig-Hallum set a target price of $109.0 on 11/03/2025
Full Release
SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.
Webcast Details
Apogee Therapeutics’ live webcast of the Phase 2 APEX Part A results will begin on Monday, March 23
rd
at 8:00 a.m. ET. The live webcast can be accessed via this
link
or the Investors section on the Company’s website at
https://investors.apogeetherapeutics.com/news-events/events
. A replay of the webcast will be available following the call.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit
https://apogeetherapeutics.com
.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
[email protected]
Media Contact:
Dan Budwick
1AB Media
[email protected]
